National Institutes of Health/National Institute Of Allergy and Infectious Diseases (NIH/NIAID)
1P01AI138938-S1
米国
引用
ジャーナル: Cell Host Microbe / 年: 2022 タイトル: Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers. 著者: Kanika Vanshylla / Chengcheng Fan / Marie Wunsch / Nareshkumar Poopalasingam / Matthijs Meijers / Christoph Kreer / Franziska Kleipass / Denis Ruchnewitz / Meryem S Ercanoglu / Henning Gruell ...著者: Kanika Vanshylla / Chengcheng Fan / Marie Wunsch / Nareshkumar Poopalasingam / Matthijs Meijers / Christoph Kreer / Franziska Kleipass / Denis Ruchnewitz / Meryem S Ercanoglu / Henning Gruell / Friederike Münn / Kai Pohl / Hanna Janicki / Tobias Nolden / Simone Bartl / Saskia C Stein / Max Augustin / Felix Dewald / Lutz Gieselmann / Philipp Schommers / Thomas F Schulz / Leif Erik Sander / Manuel Koch / Marta Łuksza / Michael Lässig / Pamela J Bjorkman / Florian Klein / 要旨: A fraction of COVID-19 convalescent individuals mount a potent antibody response to SARS-CoV-2 with cross-reactivity to SARS-CoV-1. To uncover their humoral response in detail, we performed single B ...A fraction of COVID-19 convalescent individuals mount a potent antibody response to SARS-CoV-2 with cross-reactivity to SARS-CoV-1. To uncover their humoral response in detail, we performed single B cell analysis from 10 SARS-CoV-2 elite neutralizers. We isolated and analyzed 126 monoclonal antibodies, many of which were sarbecovirus cross-reactive, with some displaying merbecovirus- and embecovirus-reactivity. Several isolated broadly neutralizing antibodies were effective against B.1.1.7, B.1.351, B.1.429, B.1.617, and B.1.617.2 variants and 19 prominent potential escape sites. Furthermore, assembly of 716,806 SARS-CoV-2 sequences predicted emerging escape variants, which were also effectively neutralized. One of these broadly neutralizing potent antibodies, R40-1G8, is a IGHV3-53 RBD-class-1 antibody. Remarkably, cryo-EM analysis revealed that R40-1G8 has a flexible binding mode, targeting both "up" and "down" conformations of the RBD. Given the threat of emerging SARS-CoV-2 variants, we demonstrate that elite neutralizers are a valuable source for isolating ultrapotent antibody candidates to prevent and treat SARS-CoV-2 infection.
A: Spike glycoprotein H: R40-1G8 Fab heavy chain L: R40-1G8 Fab light chain B: Spike glycoprotein M: R40-1G8 Fab heavy chain N: R40-1G8 Fab light chain C: Spike glycoprotein P: R40-1G8 Fab heavy chain Q: R40-1G8 Fab light chain ヘテロ分子